ERBB2 and neoplasm: Trastuzumab also activates the immune system through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), recruiting phagocytic immune cells to recognize and destroy HER-2-positive tumor cells [49,50].